Jefferies adjusted its price target for Paychex, Inc. (NASDAQ:PAYX) to $110, indicating a potential downside of approximately -2.03%.The stock experienced a decrease of about 1.72% during the trading day, with a fluctuation between $109.03 and $114.12.Paychex's market capitalization stands at approximately $40.44 billion, with a 52-week range of $161.24 to $108, showcasing significant industry presence and volatility.Paychex, Inc. (NASDAQ:PAYX) is a leading provider of payroll, human resource, and benefits ...

Group 1 - Morgan Stanley raised the price target on V2X (VVX) to $61 from $58 while maintaining an Underweight rating on the shares [1] - The firm observes encouraging signs of backlog growth heading into the new year [1] - Significant drivers of performance will include contract ramp-up and roll-offs, as well as alignment to market subverticals [1]

BofA lowered the firm’s price target on AbbVie (ABBV) to $233 from $248 and keeps a Neutral rating on the shares. The firm, which sees “a relatively clean setup” for growth at the high end of the peer group being balanced by a premium multiple and limited late-stage pipeline catalysts, is shifting its valuation basis to its FY27 estimates. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisi ...

D. Boral Capital analyst Jason Kolbert raised the firm’s price target on Quince Therapeutics (QNCX) to $5 from $4 and keeps a Buy rating on the shares after the company said the last patient has completed their last visit in the pivotal Phase 3 NEAT clinical trial evaluating encapsulated dexamethasone sodium phosphate in patients with Ataxia-Telangiectasia. The firm cites the rolling of its valuation metrics out a year for the target bump. Claim 50% Off TipRanks Premium and Invest with Confidence Unloc ...

Group 1 - Cantor Fitzgerald raised the price target on Mirum Pharmaceuticals (MIRM) to $130 from $95, maintaining an Overweight rating on the shares [1] - Mirum's proposed acquisition of Bluejay Therapeutics is valued at $250 million in cash, $300 million in stock, and $200 million in tiered milestone payments, which is considered a "steal" by the analyst [1]

Core Insights - Victoria's Secret & Co reported better-than-expected third-quarter financial results, with losses of 27 cents per share compared to the analyst consensus estimate of 59 cents per share, and quarterly sales of $1.472 billion exceeding the estimate of $1.410 billion [1] - The company raised its FY2025 adjusted EPS guidance from $1.80-$2.20 to $2.40-$2.65 and increased its sales guidance from $6.330 billion-$6.410 billion to $6.450 billion-$6.480 billion [2] - CEO Hillary Super highlighted a 9% increase in net sales year-over-year, driven by strong performance across Victoria's Secret, PINK, and Beauty, and expressed confidence in the company's outlook for the holiday season [3] Financial Performance - Quarterly losses were reported at 27 cents per share, beating the consensus estimate of 59 cents [1] - Quarterly sales reached $1.472 billion, surpassing the analyst consensus estimate of $1.410 billion [1] - Net sales increased by 9% compared to the previous year [3] Guidance Updates - FY2025 adjusted EPS guidance was raised to $2.40-$2.65 from $1.80-$2.20 [2] - FY2025 sales guidance was increased to $6.450 billion-$6.480 billion from $6.330 billion-$6.410 billion [2] Analyst Reactions - Telsey Advisory Group maintained a Market Perform rating and raised the price target from $45 to $50 [6] - UBS maintained a Buy rating and increased the price target from $46 to $60 [6] - Goldman Sachs maintained a Neutral rating and raised the price target from $32 to $47 [6]

JPMorgan raised the firm’s price target on Okta (OKTA) to $121 from $115 and keeps an Overweight rating on the shares. The company reported a “beat and raise” quarter with “healthy” sales execution, the analyst tells investors in a research note. TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now ...

Core Viewpoint - RBC Capital analyst Elvira Scotto has raised the price target for Western Midstream (WES) to $42 from $39 while maintaining a Sector Perform rating on the shares, reflecting an update to the firm's model following the company's recent Q3 earnings and expectations for 2025 adjusted EBITDA guidance [1] Group 1 - The increase in price target indicates a positive outlook for Western Midstream's financial performance [1] - The company is expected to be near the high-end of its 2025 adjusted EBITDA guidance, suggesting strong operational performance [1] - Western Midstream's robust balance sheet is highlighted as a key factor providing financial flexibility for growth plans and supporting operations during commodity price fluctuations [1]

Core Viewpoint - RBC Capital has lowered the price target for Deere (DE) to $541 from $542 while maintaining an Outperform rating on the shares, indicating a positive outlook despite the slight reduction in target price [1]. Financial Performance - Deere reported solid Q4 results, although net income was below consensus expectations, impacted by approximately $1.2 billion of pre-tax tariff effects [1]. - The introduction of F26 guidance reflects the company's strategic planning for future performance [1]. Inventory and Operations - RBC Capital views Deere's progress in inventory management and growth in Equipment Operations positively, suggesting a strong operational foundation for the company [1].

Group 1 - B. Riley has lowered the price target on PDS Biotechnology (PDSB) to $3 from $5 while maintaining a Buy rating on the shares [1] - The shares are considered attractively valued with near-zero enterprise value (EV) that does not reflect the impact of the recent strategic pivot on enrollment size, efficacy endpoint durations, and an enriched p16+ve population with limited competing trials [1]